Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer

When treating patients with unresectable stage III non-small-cell lung cancer (NSCLC), those with a good performance status and disease measured within a radical treatment volume should be considered for definitive concurrent chemoradiotherapy (cCRT). This guidance is based on key scientific rationa...

Descripción completa

Detalles Bibliográficos
Autor principal: Conibear, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735212/
https://www.ncbi.nlm.nih.gov/pubmed/33293671
http://dx.doi.org/10.1038/s41416-020-01070-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735212/
https://www.ncbi.nlm.nih.gov/pubmed/33293671
http://dx.doi.org/10.1038/s41416-020-01070-6

Ejemplares similares